OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).

Jorge E. Cortes,Jane F. Apperley,Elza Lomaia,Beatriz Moiraghi,Maria Undurraga Sutton,Carolina Pavlovsky,Charles Chuah,Tomasz Sacha,Jeffrey H. Lipton,Charles A. Schiffer,James K. McCloskey,Andreas Hochhaus,Philippe Rousselot,Gianantonio Rosti,Hugues de Lavallade,Michael J. Mauro,Tracey Hall,Vickie Lu,Shouryadeep Srivastava,Michael W. Deininger

OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).

2021

7000Background: PON, a third-generation tyrosine kinase inhibitor (TKI), demonstrated deep and long-lasting responses and survival in patients (pts) with chronic-phase chronic myeloid leukemia (CP-...

Keywords:

Ponatinib
Medicine
Tyrosine-kinase inhibitor
dose optimization
in patient
Myeloid leukemia
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations